Biotech: Page 75
-
Getty Images
Pfizer stops development of once-promising heart drug, handing back rights to partner Ionis
Pfizer concluded the data didn't support advancing the ANGPTL3-targeting drug — for which it paid $250 million two years ago to acquire the rights — despite positive study results.
By Ned Pagliarulo • Jan. 31, 2022 -
Courtesy of Galapagos
Paul Stoffels, J&J's former top scientist, to lead Galapagos
Stoffels, who helped build Galapagos in its early days, is now taking helm of the biotech as it looks to recover from a recent series of setbacks.
By Kristin Jensen • Jan. 27, 2022 -
Explore the Trendline➔
Spencer Platt via Getty Images
TrendlineEmerging biotech
New biotechs continue to emerge despite a challenging market environment that has forced venture firms to build their drug startups more cautiously.
By BioPharma Dive staff -
Getty Images
Touting a new way to drug an all-important family of proteins, a startup launches with $100M
Backed by some of biotech's most powerful investors, Septerna is looking to usher in the next chapter of medicines that act on G protein-coupled receptors.
By Jacob Bell • Jan. 27, 2022 -
Photo illustration by Maura Sadovi/BioPharma Dive; photograph by Carl Court via Getty Images
Moderna follows Pfizer in beginning trial of omicron vaccine
The study will test a version of the biotech's COVID-19 shot that's tailored to the infectious variant. New data, meanwhile, help affirm the benefit of a third dose of Moderna's current vaccine.
By Jonathan Gardner • Jan. 26, 2022 -
Sarah Silbiger via Getty Images
A biotech wins the first FDA drug approval in a rare type of eye cancer
U.K.-based Immunocore's treatment, known as Kimmtrak, is also the first T cell receptor drug to have reached market in the U.S. so far.
By Jonathan Gardner • Jan. 26, 2022 -
Permission granted by Cortexyme
Cortexyme to shift focus after FDA places hold on experimental Alzheimer's drug
While a recent trial of Cortexyme's drug had failed, the biotech was planning to move ahead with another study. Now the company is cutting costs and prioritizing an earlier-stage therapy.
By Ned Pagliarulo • Jan. 26, 2022 -
Justin Sullivan via Getty Images
Gilead's oncology plans take a hit as FDA stops tests of key cancer drug
U.S. regulators halted several studies of a drug Gilead paid almost $5 billion to acquire in 2020 after researchers observed an "apparent imbalance" of serious adverse reactions.
By Ben Fidler • Jan. 26, 2022 -
Getty Images
Gene editing startup Metagenomi raises $175M to advance research pipeline
The biotech raised the Series B round during "probably one of the worst biotech markets" emerging drugmakers have faced in some time, a Metagenomi executive told BioPharma Dive.
By Ned Pagliarulo • Jan. 25, 2022 -
Permission granted by Iowa Economic Development Authority
Sponsored by Iowa Economic Development AuthorityIowa's institutions on the leading edge of next-gen vaccines and therapies
Learn more about Iowa's efforts in the ongoing fight against pandemics and other threats to human and animal health.
Jan. 24, 2022 -
Cancer biotech Zymeworks to lay off more than 100 staff in restructuring
The biotech's newly minted CEO said the 25% workforce reduction should help make Zymeworks more financially stable as it focuses on developing experimental cancer drugs and forging new deals.
By Kristin Jensen • Jan. 20, 2022 -
Carol Highsmith. (2005). "Apex Bldg." [Photo]. Retrieved from Wikimedia Commons.
Antitrust regulators aim to revamp merger guidelines, signaling threat to health sector deals
The news sparked headlines about an attempt by regulators to target big tech, but it could have serious implications for healthcare, too.
By Samantha Liss • Jan. 19, 2022 -
Permission granted by ICON
Sponsored by ICONHow CRO venture capital relationships can help biotech fundraising
A CRO can offer numerous services to biopharma and medical device companies, from drug discovery all the way through to commercialization, pharmacovigilance and post-approval activities.
Jan. 18, 2022 -
Danielle Ternes/BioPharma Dive
JPM22: Aftershocks for Lilly, CRISPR versus CRISPR and Bluebird's crucial year
A restrictive Medicare decision on Alzheimer's drugs sent Lilly shares tumbling, while the CEO of Editas brushed off competitive threats to his company's gene editing technology.
By Ned Pagliarulo , Ben Fidler • Jan. 12, 2022 -
Getty Images
Amgen partners with Arrakis to develop drugs aimed at RNA
Arrakis, a specialist in designing oral drugs that target RNA, will receive $75 million under the deal, which could be worth "several billion dollars" more.
By Ned Pagliarulo • Jan. 11, 2022 -
Yujin Kim / MedTech Dive, original photo courtesy of U.S. Food and Drug Administration
5 questions facing the FDA in 2022
If Robert Califf wins Senate confirmation as expected, he will face a lengthy agenda as well as questions on Aduhelm controversy, accelerated approval and agency funding.
By Jonathan Gardner • Jan. 11, 2022 -
Danielle Ternes/BioPharma Dive
JPM22: Pfizer's big bet on mRNA, Biogen 'proven wrong' on Aduhelm price and the next cell therapies
The healthcare conference's first day brought a trio of mRNA deals from Pfizer, a rare admission from Biogen's CEO and new focus on what's next in cell therapy.
By Ned Pagliarulo , Jonathan Gardner , Jacob Bell • Jan. 10, 2022 -
Lisa Maree Williams via Getty Images
AstraZeneca adds to rare disease drug pipeline with Neurimmune deal
Neurimmune, which will license to AstraZeneca an early-stage treatment for a rare form of cardiomyopathy, is probably best known for its invention of the antibody that became Biogen's Alzheimer's drug Aduhelm.
By Ned Pagliarulo • Jan. 7, 2022 -
Kena Betancur via Getty Images
As three biotechs head to Wall Street, a battered sector braces for a pullback
Amylyx, CinCor and Vigil raised about $480 million combined, a sign of continued investor interest in biotech IPOs. But industry analysts expect fewer and smaller offerings in 2022 due to investor fatigue from high valuations.
By Ben Fidler • Jan. 7, 2022 -
Novartis turns to Alnylam in research deal aimed at liver failure
The Swiss pharma is familiar with Alnylam's RNA-based technology, which underpins Novartis' newly approved cholesterol drug Leqvio.
By Ned Pagliarulo • Updated Jan. 6, 2022 -
Thomas Lohnes via Getty Images
Pfizer, BioNTech bet mRNA can make a better shingles vaccine
The pharma company, already partnered with BioNTech on vaccines for COVID-19 and influenza, will pay $225 million upfront to further expand its work with the German biotech.
By Ned Pagliarulo • Jan. 5, 2022 -
Getty Images
Avrobio stops work on rare disease gene therapy after unexpected study results
The biotech's gene therapy was one of the furthest along in testing for Fabry, a rare inherited disease that's become a target for drug developers.
By Ned Pagliarulo • Jan. 4, 2022 -
National Institute of Allergy and Infectious Diseases. (2020). "Novel Coronavirus SARS-CoV-2" [Micrograph]. Retrieved from Flickr.
US pauses distribution of Regeneron, Lilly antibodies over omicron concerns
The decision follows worrisome results in lab studies that indicated omicron can evade both drugs and leaves the U.S. with fewer treatments to respond to the variant's spread.
By Ben Fidler • Updated Jan. 4, 2022 -
Allakos shares plunge as company's top drug falls short in studies
The drug's effect in tissue did not appear to translate to a benefit in reducing symptoms, surprising executives at the biotech as well as its investors.
By Kristin Jensen • Dec. 22, 2021 -
Photo illustration by Maura Sadovi/BioPharma Dive; photograph by Carl Court via Getty Images
Moderna vaccine weaker against omicron, but third shot boosts protection
As a result of new laboratory data, the biotech company is deemphasizing more complex "multivalent" booster shots in favor of further study of its existing formulation and an omicron-specific version.
By Jonathan Gardner • Dec. 20, 2021 -
Getty Images
FDA OKs drugs from Amgen, Argenx, Intra-Cellular in year-end push
The flurry of decisions from the regulator clears for market Amgen and AstraZeneca's asthma treatment Tezspire, Argenx's rare disease drug Vyvgart and Intra-Cellular's Caplyta for bipolar depression.
By Ned Pagliarulo • Dec. 20, 2021
Previous
